Oramed Pharmaceuticals Inc. — Director's Dealing 2017

Mar 2, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2017-02-09

Reporting Person: Friedman Aviad (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-09	Stock Option (right to buy)	$1.00	A	4084	Acquired	2027-02-09	Common Stock (4084)	Direct

Footnotes

F1: The Stock Option will vest immediately.